NEW YORK – Israeli liquid biopsy startup Nucleix said on Wednesday that it has raised $55 million in an oversubscribed financing round.
The Rehovot-based firm will use the funds to continue development of its EpiCheck methylation platform and to develop its Lung EpiCheck assay for the early detection of lung cancer.